These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 9166950)

  • 21. Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer.
    Jones SE; Clark G; Koleszar S; Ethington G; Mennel R; Paulson S; Brooks B; Kerr R; Denham C; Savin M; Blum J; Kirby R; Stone M; Pippen J; George T; Orr D; Knox S; Grant M; Peters G; Savino D; Rietz C
    Clin Breast Cancer; 2002 Jun; 3(2):147-52. PubMed ID: 12123539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
    Boccardo F; Rubagotti A; Bruzzi P; Cappellini M; Isola G; Nenci I; Piffanelli A; Scanni A; Sismondi P; Santi L
    J Clin Oncol; 1990 Aug; 8(8):1310-20. PubMed ID: 2199618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cigarette smoking and risk of prostate cancer: a population-based case-control study in Ontario and British Columbia, Canada.
    Rohan TE; Hislop TG; Howe GR; Gallagher RP; Teh CZ; Ghadirian P
    Eur J Cancer Prev; 1997 Aug; 6(4):382-8. PubMed ID: 9370102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of relapse in breast cancer: changes over time.
    Yerushalmi R; Woods R; Kennecke H; Speers C; Knowling M; Gelmon K
    Breast Cancer Res Treat; 2010 Apr; 120(3):753-9. PubMed ID: 19701704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secondary prevention after acute myocardial infarction in four Canadian provinces, 1997-2000.
    Pilote L; Beck CA; Karp I; Alter D; Austin P; Cox J; Humphries K; Jackevicius C; Richard H; Tu JV;
    Can J Cardiol; 2004 Jan; 20(1):61-7. PubMed ID: 14968144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy.
    Nogi H; Uchida K; Mimoto R; Kamio M; Shioya H; Toriumi Y; Suzuki M; Nagasaki E; Kobayashi T; Takeyama H
    Clin Breast Cancer; 2017 Dec; 17(8):644-649. PubMed ID: 28601382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant therapy of node-negative breast cancer.
    Hall PD; Lesher BA; Hall RK
    Ann Pharmacother; 1995 Mar; 29(3):289-98. PubMed ID: 7606076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
    Tormey DC; Gray R; Falkson HC
    J Natl Cancer Inst; 1996 Dec; 88(24):1828-33. PubMed ID: 8961972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
    Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
    Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle.
    Ludwig Breast Cancer Study Group
    N Engl J Med; 1988 Sep; 319(11):677-83. PubMed ID: 2901037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of systemic breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal" therapy.
    Fong A; Shafiq J; Saunders C; Thompson A; Tyldesley S; Olivotto IA; Barton MB; Dewar JA; Jacob S; Ng W; Speers C; Delaney GP
    Breast; 2012 Aug; 21(4):562-9. PubMed ID: 22297168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study.
    Montero AJ; Rouzier R; Lluch A; Theriault RL; Buzdar AU; Delaloge S; Bermejo B; Le M; Kau SW; Dunant A; Arriagada R; Spielmann M; Garcia-Conde J; Sahin AA; Singletary SE; Hortobagyi GN; Valero V
    Cancer; 2005 Jul; 104(2):229-35. PubMed ID: 15937910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials.
    Taghian AG; Jeong JH; Mamounas EP; Parda DS; Deutsch M; Costantino JP; Wolmark N
    J Clin Oncol; 2006 Aug; 24(24):3927-32. PubMed ID: 16921044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype.
    Alramadhan M; Ryu JM; Rayzah M; Nam SJ; Kim SW; Yu J; Lee SK; Bae SY; Park S; Paik HJ; Lee JE
    Breast; 2016 Dec; 30():111-117. PubMed ID: 27697675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The administration of adjuvant chemo(-immuno) therapy in the post ACOSOG-Z0011 era; a population based study.
    Poodt IGM; Rots ML; Vugts G; van Dalen T; Kuijer A; Vriens BEPJ; Nieuwenhuijzen GAP; Schipper RJ
    Eur J Surg Oncol; 2018 Aug; 44(8):1151-1156. PubMed ID: 29580733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of adjuvant tamoxifen: the latest results from the Cancer Research Campaign Adjuvant Breast Trial. Cancer Research Campaign Breast Cancer Trials Group.
    Eur J Cancer; 1992; 28A(4-5):904-7. PubMed ID: 1524921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
    National Institutes of Health Consensus Development Panel
    J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of patients with hormone receptor-positive breast cancer who need adjuvant tamoxifen therapy for more than 5 years.
    Wu CE; Chen SC; Chang HK; Lo YF; Hsueh S; Lin YC
    J Formos Med Assoc; 2016 Apr; 115(4):249-56. PubMed ID: 25900861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.